Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.

Zhang L, Liu N, Xie S, He X, Zhou J, Liu M, Li D.

Cancer Biol Ther. 2014;15(11):1561-70. doi: 10.4161/15384047.2014.956632.

2.

Bioactive heterocycles containing endocyclic N-hydroxy groups.

Rani R, Granchi C.

Eur J Med Chem. 2015 Jun 5;97:505-24. doi: 10.1016/j.ejmech.2014.11.031. Review.

3.

From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.

Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.

J Natl Cancer Inst. 2013 Oct 2;105(19):1441-56. doi: 10.1093/jnci/djt209. Review.

4.

RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.

Zhan Q, Tsai S, Lu Y, Wang C, Kwan Y, Ngai S.

PLoS One. 2013 Aug 16;8(8):e71663. doi: 10.1371/journal.pone.0071663.

5.

Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, Bradner JE, Tolliday N, Stegmaier K.

Chem Biol. 2013 May 23;20(5):713-25. doi: 10.1016/j.chembiol.2013.03.020.

6.

Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Cheung NK, Dyer MA.

Nat Rev Cancer. 2013 Jun;13(6):397-411. doi: 10.1038/nrc3526. Review.

8.

The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.

Lautz TB, Jie C, Clark S, Naiditch JA, Jafari N, Qiu YY, Zheng X, Chu F, Madonna MB.

PLoS One. 2012;7(7):e40816. doi: 10.1371/journal.pone.0040816.

9.

Epigenetic changes in pediatric solid tumors: promising new targets.

Lawlor ER, Thiele CJ.

Clin Cancer Res. 2012 May 15;18(10):2768-79. doi: 10.1158/1078-0432.CCR-11-1921. Review.

10.

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Carpenter EL, Mossé YP.

Nat Rev Clin Oncol. 2012 May 15;9(7):391-9. doi: 10.1038/nrclinonc.2012.72. Review.

12.

Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.

Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V.

Eur J Cancer. 2010 Oct;46(15):2771-80. doi: 10.1016/j.ejca.2010.05.010.

13.

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Marks PA.

Expert Opin Investig Drugs. 2010 Sep;19(9):1049-66. doi: 10.1517/13543784.2010.510514. Review.

14.

Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Marks PA.

Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):717-25. doi: 10.1016/j.bbagrm.2010.05.008. Review.

15.

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

Tan J, Cang S, Ma Y, Petrillo RL, Liu D.

J Hematol Oncol. 2010 Feb 4;3:5. doi: 10.1186/1756-8722-3-5. Review.

16.

Epigenetic mechanisms of regulation of Foxp3 expression.

Lal G, Bromberg JS.

Blood. 2009 Oct 29;114(18):3727-35. doi: 10.1182/blood-2009-05-219584. Review.

17.

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9751-6. doi: 10.1073/pnas.0710413105.

18.

Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.

Mühlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM, Gross N.

Mol Cancer. 2008 Jun 12;7:55. doi: 10.1186/1476-4598-7-55.

19.

A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.

Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R.

Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17777-82.

20.

Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?

Dashwood RH, Myzak MC, Ho E.

Carcinogenesis. 2006 Feb;27(2):344-9. Review.

Items per page

Supplemental Content

Support Center